-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 22, Genetron Health announced that it had signed an exclusive commercial cooperation agreement with Jiangsu Fosun Pharmaceutical, a subsidiary of Shanghai Fosun Pharmaceutical Holdings, on Genetron Health's Seq-MRD® (hematological minimal residual disease) detection service
According to the agreement, Genetron Health and Jiangsu Fosun Pharma will jointly sell and jointly promote Seq-MRD® in key hospitals and clinics for hematological diseases in designated areas in China to serve acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia Waiting for patients with lymphatic hematological tumors
In the process of cooperation, Jiangsu Fosun Pharma will use its clinics, hospitals and distributors and other terminal channel resources to gather a large-scale and experienced hematological tumor professional marketing team to serve the clinical promotion and market of the Seq-MRD® project Application
Seq-MRD® is a molecular diagnostic method for detecting and monitoring minimal residual disease in specific hematological tumors